GoodRx, Boehringer Increase Affordable Drug Access for Patients
Patients with diabetes and COPD now have more affordable drug access to Boehringer Ingelheim’s portfolio of medications through the GoodRx platform.
Source: Getty Images
By - GoodRx and Boehringer Ingelheim recently collaborated to increase affordable drug access for patients with type 2 diabetes or chronic obstructive pulmonary disease (COPD).
Under the collaboration, patients with diabetes and COPD can now easily enroll in manufacturer-sponsored copay savings programs for Boehringer Ingelheim’s portfolio of medications through the GoodRx platform.
The initiative will help reduce out-of-pocket costs for patients, potentially including additional medications in the integration in the future.
The integration and proposed integrations have the potential to deliver nearly $15 million in available savings a year for those that need life-enhancing medications, a GoodRx spokesperson stated.
“As insurance deductibles increase, fewer medications are covered by insurance, and more restrictions are placed on the medications that are covered, patients are left carrying more of the economic burden,” Bansi Nagji, president of healthcare at GoodRx, said in the announcement.
“The integration of Boehringer Ingelheim savings programs will help lower the affordability barrier for patients so they can better access the medications they need,” Nagji continued.
CDC stated that diabetes affects one in 10 Americans each year, while COPD affects over 16 million people and is the third leading cause of death by disease in the US. The combined economic burden of these conditions is about $286 billion in direct medical costs annually.
Consumers looking for manufacturer savings programs for diabetes or COPD can go to the GoodRx website to find options available from Boehringer Ingelheim.
Savings programs for prescriptions of Jardiance, Synjardy, Synjardy XR, Spiriva Respimat, Stiolto Respimat, and Combivent Respimat are available to patients that qualify.
“The combination of Boehringer Ingelheim’s innovative approach to bringing transformative therapies to market and GoodRx’s trusted brand and reach, means that we will be able to provide more patients with seamless access to our support and savings programs,” said Chris Marsh, senior vice president of Market Access at Boehringer Ingelheim.
“We look forward to expanding our collaborative partnership with GoodRx so we can help more people living with chronic conditions,” Marsh continued.
Products in the collaboration also include Boehringer Ingelheim and Eli Lilly and Company alliance portfolio.
Eli Lilly and Company has worked in diabetes care since 1923 to meet the needs of people with diabetes and those who care for them.
In May, the company signed strategic international agreements with four companies to advance connected solutions and streamline diabetes care for individuals living with the disease outside the US.
The companies that are part of the agreement include DexCom, Glooko Inc, myDiabby Healthcare, and Roche.
